Fall of the mutants: T cells targeting BCR-ABL.

Targeting the tumor-specific junction sequence produced by the BCR-ABL fusion has long been an attractive strategy and, in this issue of Blood, Comoli et al demonstrate, for the first time in humans, clinical benefit with infusions of p190BCR-ABL neoantigen-specific T cells to 3 patients with active Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).